RNA5SP195: A Potential Drug Target and Biomarker (G100873457)

Target Name: RNA5SP195

NCBI ID: G100873457

RNA5SP195

Other Name(s): RNA, 5S ribosomal pseudogene 195 | RN5S195

RNA5SP195: A Potential Drug Target and Biomarker

RNA5SP195 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell鈥檚 response to infection and inflammation, and its dysfunction has been linked to a number of diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders.

The Discovery of RNA5SP195

RNA5SP195 was first identified using RNA sequencing technology as a highly expressed gene in the blood of individuals with type 2 diabetes. It is located on chromosome 6 and has a length of 211 nucleotides. RNA5SP195 has been shown to be highly expressed in various tissues and cells, including pancreatic beta cells, macrophages, and blood vessels.

Function and Interaction of RNA5SP195

RNA5SP195 has been shown to play a key role in the regulation of immune and inflammatory responses. It is a negative regulator of the T-cell receptor alpha chain, which is responsible for cell signaling and immune response. RNA5SP195 has been shown to repress the activity of the T-cell receptor alpha chain, thereby inhibiting the immune response.

In addition to its role in immune regulation, RNA5SP195 has also been shown to play a key role in the regulation of inflammation. It is a negative regulator of the pro-inflammatory molecule, nuclear factor kappa B (NF-kappa-B), which is responsible for generating inflammatory cytokines. RNA5SP195 has been shown to repress the activity of NF-kappa-B, thereby inhibiting the production of inflammatory cytokines.

Potential Therapeutic Applications

The potential therapeutic applications of RNA5SP195 are vast and varied. One of its potential therapeutic applications is as a treatment for type 2 diabetes. Given its role in immune and inflammatory regulation, RNA5SP195 could be used to improve insulin sensitivity and reduce the risk of complications associated with type 2 diabetes.

In addition to its potential as a treatment for type 2 diabetes, RNA5SP195 has also been shown to have potential therapeutic applications in a number of other diseases. For example, it has been shown to be a potential therapeutic target for a variety of neurodegenerative disorders, including Alzheimer鈥檚 disease and Parkinson鈥檚 disease.

RNA5SP195 has also been shown to have potential therapeutic applications in cancer treatment. Given its role in immune and inflammatory regulation, RNA5SP195 could be used to enhance the effectiveness of cancer treatments by improving the immune response and reducing the production of inflammatory cytokines.

Conclusion

In conclusion, RNA5SP195 is a promising drug target and biomarker with potential therapeutic applications in a variety of diseases. Its regulation of immune and inflammatory responses makes it an attractive target for drug development, and its function as a negative regulator of the T-cell receptor alpha chain and NF-kappa-B suggests that it may have a wide range of potential applications in a variety of fields. Further research is needed to fully understand the role of RNA5SP195 in disease and to develop effective therapies based on its properties.

Protein Name: RNA, 5S Ribosomal Pseudogene 195

The "RNA5SP195 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP195 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets